~/antibiotic-mcqs/antibiotic_150_MCQs_PharmD_SPLE.md

# 150 High-Yield Antibiotic MCQs — PharmD SPLE Preparation

**Topics Covered:** Mechanisms of Action | Clinical Uses | Adverse Drug Reactions | Contraindications | Pharmacokinetics | Drug Interactions | Resistance Mechanisms | Special Populations

---

## SECTION 1: BETA-LACTAMS (Penicillins, Cephalosporins, Carbapenems, Monobactams)

**Q1.** What is the primary mechanism of action of penicillins?

A) Inhibit DNA gyrase
B) Inhibit transpeptidase (PBPs), blocking peptidoglycan cross-linking
C) Inhibit 50S ribosomal subunit
D) Disrupt cell membrane integrity

**Answer: B**
*Penicillins bind to penicillin-binding proteins (PBPs/transpeptidase), preventing cross-linking of peptidoglycan in the bacterial cell wall, leading to cell lysis.*

---

**Q2.** A patient receiving penicillin G develops anaphylaxis. Which of the following is the MOST likely cause?

A) Inhibition of prostaglandin synthesis
B) IgE-mediated hypersensitivity to the beta-lactam ring
C) Direct mast cell degranulation
D) Complement activation

**Answer: B**
*Penicillin hypersensitivity is predominantly IgE-mediated (Type I) involving the beta-lactam/penicilloyl determinants.*

---

**Q3.** Which penicillin is MOST active against Pseudomonas aeruginosa?

A) Amoxicillin
B) Ampicillin
C) Piperacillin
D) Oxacillin

**Answer: C**
*Piperacillin (an anti-pseudomonal penicillin, often combined with tazobactam) has the broadest gram-negative coverage including Pseudomonas.*

---

**Q4.** Nafcillin is used primarily to treat infections caused by:

A) Pseudomonas aeruginosa
B) Methicillin-resistant Staphylococcus aureus (MRSA)
C) Methicillin-sensitive Staphylococcus aureus (MSSA)
D) Streptococcus pneumoniae

**Answer: C**
*Nafcillin (and oxacillin) are beta-lactamase-resistant penicillins used for MSSA infections. They are NOT effective against MRSA.*

---

**Q5.** Which is the most common adverse effect of high-dose penicillin G therapy (>20 million units/day IV)?

A) Hepatotoxicity
B) Seizures (neurotoxicity)
C) Nephrotoxicity
D) Ototoxicity

**Answer: B**
*Very high-dose penicillin G can cross the blood-brain barrier and cause seizures, especially in patients with renal failure.*

---

**Q6.** A patient allergic to penicillin needs antibiotic therapy. Which antibiotic class has the HIGHEST cross-reactivity with penicillin?

A) Monobactams (aztreonam)
B) Carbapenems
C) Aminoglycosides
D) Tetracyclines

**Answer: B**
*Carbapenems share the beta-lactam ring and have about 1% cross-reactivity with penicillin. Aztreonam (monobactam) has virtually no cross-reactivity.*

---

**Q7.** The mechanism of beta-lactamase inhibitors (e.g., clavulanic acid) is:

A) They directly kill bacteria
B) They irreversibly bind and inhibit beta-lactamase enzymes
C) They enhance renal excretion of penicillin
D) They prevent absorption of beta-lactamase from intestine

**Answer: B**
*Clavulanic acid, sulbactam, and tazobactam are "suicide inhibitors" that irreversibly inactivate beta-lactamase enzymes, protecting the companion penicillin.*

---

**Q8.** Which cephalosporin generation has the BEST activity against MRSA?

A) First generation
B) Second generation
C) Third generation
D) Fifth generation (ceftaroline)

**Answer: D**
*Ceftaroline (5th generation) is unique among cephalosporins for activity against MRSA because it binds PBP2a, the altered PBP in MRSA.*

---

**Q9.** A patient develops bloody diarrhea 3 weeks after completing a cephalosporin course. What is the MOST likely diagnosis?

A) Salmonellosis
B) Clostridium difficile colitis (CDI/CDAD)
C) Shigellosis
D) Campylobacter enteritis

**Answer: B**
*Broad-spectrum cephalosporins disrupt normal flora, predisposing to C. difficile overgrowth and pseudomembranous colitis.*

---

**Q10.** Which cephalosporin is the drug of choice for surgical prophylaxis?

A) Cefepime
B) Ceftriaxone
C) Cefazolin
D) Cefoxitin

**Answer: C**
*Cefazolin (1st generation) is the standard agent for surgical prophylaxis due to its narrow spectrum, excellent coverage of gram-positive organisms, and cost-effectiveness.*

---

**Q11.** Third-generation cephalosporins (ceftriaxone, cefotaxime) are particularly useful for:

A) MRSA bacteremia
B) Gram-negative meningitis and gonorrhea
C) Anaerobic abdominal infections
D) Pseudomonas UTI

**Answer: B**
*3rd-generation cephalosporins have excellent CNS penetration, are first-line for gram-negative meningitis (H. influenzae, Neisseria meningitidis) and uncomplicated gonorrhea.*

---

**Q12.** Ceftriaxone is contraindicated in neonates with hyperbilirubinemia because:

A) It causes gray baby syndrome
B) It displaces bilirubin from albumin, risking kernicterus
C) It causes hemolytic anemia
D) It inhibits bilirubin conjugation

**Answer: B**
*Ceftriaxone competes with bilirubin for albumin binding sites; free bilirubin can then cross the blood-brain barrier causing kernicterus.*

---

**Q13.** Imipenem is administered with cilastatin primarily to:

A) Enhance antibacterial spectrum
B) Prevent hydrolysis of imipenem by renal dehydropeptidase-I
C) Reduce nephrotoxicity of imipenem
D) Improve oral bioavailability

**Answer: B**
*Cilastatin is a dehydropeptidase-I inhibitor that prevents renal tubular degradation of imipenem, thereby increasing urinary concentrations and reducing nephrotoxic metabolites.*

---

**Q14.** Which carbapenem has the LOWEST seizure risk?

A) Imipenem
B) Meropenem
C) Ertapenem
D) Doripenem

**Answer: B**
*Meropenem has the lowest seizure potential among carbapenems. Imipenem has the highest due to its GABA receptor antagonism.*

---

**Q15.** Aztreonam (monobactam) is active against:

A) Gram-positive organisms only
B) Gram-negative aerobic bacteria only
C) Anaerobes only
D) Broad-spectrum including fungi

**Answer: B**
*Aztreonam has a very narrow spectrum - active ONLY against aerobic gram-negative bacteria (including Pseudomonas). It is safe in penicillin-allergic patients.*

---

## SECTION 2: GLYCOPEPTIDES (Vancomycin, Teicoplanin, Dalbavancin)

**Q16.** What is the mechanism of action of vancomycin?

A) Inhibits 50S ribosomal subunit
B) Binds to D-Ala-D-Ala terminus of peptidoglycan precursors, inhibiting cell wall synthesis
C) Disrupts the outer membrane of gram-negative bacteria
D) Inhibits DNA gyrase

**Answer: B**
*Vancomycin binds to the D-Ala-D-Ala dipeptide terminus of peptidoglycan precursors, blocking transglycosylation and transpeptidation steps of cell wall synthesis.*

---

**Q17.** Vancomycin is the drug of choice for:

A) Penicillin-sensitive Streptococcus pneumoniae meningitis
B) MRSA infections
C) Gram-negative sepsis
D) Pseudomonas pneumonia

**Answer: B**
*Vancomycin is first-line therapy for serious MRSA infections including bacteremia, endocarditis, pneumonia, and meningitis.*

---

**Q18.** A patient receiving IV vancomycin develops flushing, erythema, and pruritus over the face, neck, and upper torso during infusion. This is called:

A) Stevens-Johnson syndrome
B) Red man syndrome
C) Anaphylaxis
D) Fixed drug eruption

**Answer: B**
*Red man syndrome is a rate-related infusion reaction (not a true allergy) caused by non-IgE-mediated mast cell degranulation. It is prevented by slowing the infusion rate.*

---

**Q19.** Vancomycin monitoring is required because of its potential for:

A) Hepatotoxicity and pancreatitis
B) Nephrotoxicity and ototoxicity
C) Cardiotoxicity
D) Hematological toxicity

**Answer: B**
*Vancomycin is nephrotoxic (especially with aminoglycosides) and ototoxic (tinnitus, hearing loss). Trough levels and AUC/MIC monitoring guide dosing.*

---

**Q20.** Vancomycin-resistant Enterococcus (VRE) is resistant due to:

A) Production of beta-lactamase
B) Modification of D-Ala-D-Ala to D-Ala-D-Lactate (vanA gene)
C) Efflux pumps
D) Outer membrane impermeability

**Answer: B**
*VanA resistance changes the terminal D-Ala-D-Ala to D-Ala-D-Lac, which has 1000-fold lower affinity for vancomycin.*

---

**Q21.** Oral vancomycin is used for:

A) MRSA bacteremia
B) Clostridium difficile colitis
C) Gram-negative UTI
D) It is not absorbed orally, so it has no use

**Answer: B**
*Oral vancomycin is not absorbed systemically but achieves high GI concentrations - used to treat C. difficile colitis (along with fidaxomicin).*

---

## SECTION 3: AMINOGLYCOSIDES

**Q22.** What is the mechanism of action of aminoglycosides?

A) Inhibit cell wall synthesis
B) Bind to 30S ribosomal subunit causing misreading of mRNA
C) Inhibit RNA polymerase
D) Inhibit topoisomerase II

**Answer: B**
*Aminoglycosides (gentamicin, tobramycin, amikacin) bind irreversibly to the 30S ribosomal subunit, causing codon misreading, incorporation of wrong amino acids, and faulty protein synthesis.*

---

**Q23.** Which organism is aminoglycosides MOST active against?

A) Gram-positive anaerobes
B) Aerobic gram-negative bacilli
C) Mycobacterium tuberculosis (as single agent)
D) Clostridium species

**Answer: B**
*Aminoglycosides are bactericidal against aerobic gram-negative bacilli (E. coli, Klebsiella, Pseudomonas, Serratia). They have poor activity in anaerobic conditions.*

---

**Q24.** The most serious adverse effects of aminoglycosides are:

A) Hepatotoxicity and hypoglycemia
B) Nephrotoxicity and ototoxicity
C) QT prolongation and arrhythmias
D) Bone marrow suppression

**Answer: B**
*Aminoglycosides accumulate in the renal cortex (nephrotoxicity) and cochlea/vestibule (ototoxicity - both auditory and vestibular damage via free radical generation in hair cells).*

---

**Q25.** Once-daily dosing of aminoglycosides (extended-interval dosing) is used because:

A) It reduces the risk of nephrotoxicity by limiting accumulation
B) It increases the bactericidal effect through concentration-dependent killing
C) Both A and B
D) Neither A nor B

**Answer: C**
*Aminoglycosides exhibit concentration-dependent killing (higher peak = better kill). Once-daily dosing achieves higher peaks and a post-antibiotic effect while reducing toxicity by allowing drug-free intervals.*

---

**Q26.** Aminoglycosides should be used with CAUTION (or avoided) in patients with:

A) Hypertension
B) Myasthenia gravis
C) Diabetes mellitus
D) Hyperthyroidism

**Answer: B**
*Aminoglycosides can cause neuromuscular blockade by inhibiting presynaptic calcium uptake and acetylcholine release, which can precipitate respiratory arrest in myasthenia gravis patients.*

---

**Q27.** Streptomycin is particularly used in the treatment of:

A) MRSA endocarditis
B) Tuberculosis and brucellosis
C) C. difficile colitis
D) VRE infections

**Answer: B**
*Streptomycin was the first aminoglycoside and is still used in TB (streptomycin-sensitive TB) and brucellosis (with doxycycline).*

---

**Q28.** Which aminoglycoside is MOST resistant to inactivating enzymes and is used for multidrug-resistant gram-negative infections?

A) Gentamicin
B) Tobramycin
C) Amikacin
D) Neomycin

**Answer: C**
*Amikacin is resistant to most aminoglycoside-inactivating enzymes (acetyltransferases, phosphotransferases, nucleotidyltransferases) and is reserved for MDR gram-negative infections.*

---

## SECTION 4: TETRACYCLINES & GLYCYLCYCLINES

**Q29.** What is the mechanism of action of tetracyclines?

A) Inhibit cell wall synthesis
B) Bind 30S ribosomal subunit and block aminoacyl-tRNA binding
C) Inhibit RNA polymerase
D) Disrupt cell membrane

**Answer: B**
*Tetracyclines enter bacteria by active transport, bind reversibly to the 30S ribosomal subunit, and block attachment of aminoacyl-tRNA to the A-site, inhibiting protein synthesis (bacteriostatic).*

---

**Q30.** Tetracyclines are contraindicated in:

A) Patients with renal failure only
B) Pregnant women and children under 8 years
C) Elderly patients
D) Patients on beta-blockers

**Answer: B**
*Tetracyclines chelate calcium and deposit in developing bones and teeth, causing permanent discoloration and enamel hypoplasia in children under 8 and the fetus.*

---

**Q31.** A patient on tetracycline also takes antacids (containing Mg2+, Al3+, or Ca2+). What interaction occurs?

A) Antacids accelerate tetracycline absorption
B) Tetracycline chelates divalent/trivalent cations, reducing absorption
C) Antacids cause tetracycline toxicity
D) No significant interaction

**Answer: B**
*Tetracyclines form insoluble chelates with divalent/trivalent cations (calcium, magnesium, aluminum, iron), markedly reducing GI absorption. They should be taken 1-2 hours before or 4-6 hours after antacids.*

---

**Q32.** Doxycycline is the preferred tetracycline for patients with renal impairment because:

A) It is primarily eliminated by the liver/feces, not the kidneys
B) It is more bactericidal than other tetracyclines
C) It does not cause nephrotoxicity at any dose
D) It undergoes no hepatic metabolism

**Answer: A**
*Doxycycline is excreted primarily via the GI tract (bile), not renally. It does not accumulate in renal failure, unlike other tetracyclines (which can worsen uremia).*

---

**Q33.** Which intracellular organisms are tetracyclines particularly effective against?

A) MRSA, VRE, Pseudomonas
B) Chlamydia, Rickettsia, Mycoplasma, Brucella
C) Clostridium, Bacteroides, Fusobacterium
D) Candida, Aspergillus, Cryptococcus

**Answer: B**
*Tetracyclines are excellent for intracellular pathogens - Chlamydia trachomatis, C. pneumoniae, Rickettsia species, Mycoplasma pneumoniae, Brucella, and also Lyme disease (Borrelia).*

---

**Q34.** Tigecycline (a glycylcycline) is unique because:

A) It covers MRSA and some carbapenem-resistant organisms, and is not affected by tetracycline efflux pumps
B) It has excellent activity against Pseudomonas aeruginosa
C) It can be used safely in children under 8
D) It is the only oral tetracycline

**Answer: A**
*Tigecycline overcomes tetracycline-specific resistance mechanisms (efflux pumps, ribosomal protection). It covers MRSA, VRE, Acinetobacter, but NOT Pseudomonas or Proteus.*

---

**Q35.** Photosensitivity is a well-known adverse effect of tetracyclines. Which tetracycline causes it MOST frequently?

A) Doxycycline
B) Minocycline
C) Tetracycline (oxytetracycline)
D) All equally

**Answer: A**
*Doxycycline causes photosensitivity most frequently. Patients should be counseled to use sunscreen and avoid prolonged sun exposure.*

---

**Q36.** Minocycline is associated with a unique adverse effect not seen with other tetracyclines:

A) Esophageal ulceration
B) Vestibular toxicity (dizziness, vertigo, ataxia)
C) Photosensitivity
D) Discoloration of teeth

**Answer: B**
*Minocycline causes dose-dependent vestibular toxicity (dizziness, vertigo, ataxia, nausea), especially in women. This limits its use.*

---

## SECTION 5: MACROLIDES, AZALIDES & KETOLIDES

**Q37.** What is the mechanism of action of macrolides (erythromycin, clarithromycin, azithromycin)?

A) Inhibit 30S ribosomal subunit
B) Bind to 23S rRNA of the 50S ribosomal subunit, blocking translocation
C) Inhibit DNA gyrase
D) Disrupt bacterial cell membrane

**Answer: B**
*Macrolides bind to the 50S ribosomal subunit (23S rRNA), blocking translocation of the peptidyl-tRNA from the A-site to the P-site, inhibiting protein synthesis.*

---

**Q38.** Azithromycin is preferred over erythromycin for community-acquired pneumonia (CAP) because:

A) It covers gram-negative organisms better
B) It has a longer half-life (~68 hours), allowing once-daily dosing and a 5-day course
C) It has fewer drug interactions
D) Both B and C

**Answer: D**
*Azithromycin has a tissue half-life of ~68 hours (vs erythromycin's ~1.5 hours), achieves high tissue concentrations, allows once-daily dosing with a 5-day Z-pak course, and has far fewer CYP450 drug interactions than erythromycin or clarithromycin.*

---

**Q39.** A patient on erythromycin and warfarin comes in with bleeding. The most likely mechanism is:

A) Erythromycin displaces warfarin from albumin
B) Erythromycin inhibits CYP3A4, increasing warfarin blood levels
C) Erythromycin causes vitamin K deficiency
D) Direct anticoagulant effect of erythromycin

**Answer: B**
*Erythromycin (and clarithromycin) are potent CYP3A4 inhibitors. This increases plasma levels of warfarin, statins, cyclosporine, and many other CYP3A4 substrates.*

---

**Q40.** Which macrolide is used to treat Helicobacter pylori infection (in triple therapy)?

A) Erythromycin
B) Azithromycin
C) Clarithromycin
D) Telithromycin

**Answer: C**
*Clarithromycin-based triple therapy (clarithromycin + amoxicillin + PPI) or clarithromycin + metronidazole + PPI is standard for H. pylori eradication.*

---

**Q41.** The most common adverse effect of erythromycin is:

A) Ototoxicity
B) GI disturbances (nausea, vomiting, abdominal cramping)
C) QT prolongation
D) Hepatotoxicity

**Answer: B**
*Erythromycin is a motilin receptor agonist, causing intense GI motility and cramping. This is the most frequent reason for non-compliance.*

---

**Q42.** Which macrolide has the GREATEST risk of QT prolongation and cardiac arrhythmias?

A) Azithromycin
B) Clarithromycin
C) Erythromycin (IV)
D) All equally

**Answer: C**
*IV erythromycin has the greatest risk. Azithromycin also prolongs QT but less so. Avoid in patients with pre-existing QT prolongation, hypokalemia, or on other QT-prolonging drugs.*

---

**Q43.** Macrolides are contraindicated with which class of drugs due to risk of fatal arrhythmia?

A) ACE inhibitors
B) Statins
C) Cisapride and other QT-prolonging agents
D) Thiazide diuretics

**Answer: C**
*Macrolides + QT-prolonging drugs (cisapride, pimozide, terfenadine) can cause fatal torsades de pointes. Cisapride was withdrawn from the US market partly due to this interaction.*

---

## SECTION 6: FLUOROQUINOLONES

**Q44.** What is the mechanism of action of fluoroquinolones?

A) Inhibit cell wall synthesis
B) Inhibit DNA gyrase (topoisomerase II) and topoisomerase IV, blocking DNA replication
C) Inhibit 50S ribosomal subunit
D) Inhibit RNA polymerase

**Answer: B**
*Fluoroquinolones inhibit bacterial DNA gyrase (topoisomerase II - primarily in gram-negatives) and topoisomerase IV (primarily in gram-positives), preventing DNA supercoiling and replication.*

---

**Q45.** Fluoroquinolones are contraindicated in:

A) Elderly patients with pneumonia
B) Children under 18 years and pregnant women
C) Patients with UTI
D) Diabetic patients

**Answer: B**
*Fluoroquinolones can damage developing cartilage (arthropathy demonstrated in animal models) and are generally avoided in children under 18 and during pregnancy, except for specific indications (e.g., ciprofloxacin for anthrax, complicated UTI when no alternatives exist).*

---

**Q46.** A patient on ciprofloxacin develops a spontaneous Achilles tendon rupture. This is a known serious adverse effect. The HIGHEST risk factor for this is:

A) Female sex
B) Concomitant corticosteroid use and age >60
C) Smoking history
D) Renal impairment

**Answer: B**
*Risk of fluoroquinolone-induced tendinopathy/rupture is markedly increased in patients >60 years AND those on corticosteroids. The FDA added a "Black Box Warning" for this.*

---

**Q47.** Which fluoroquinolone has the BEST coverage of Streptococcus pneumoniae (respiratory fluoroquinolone)?

A) Ciprofloxacin
B) Norfloxacin
C) Levofloxacin / Moxifloxacin
D) Ofloxacin

**Answer: C**
*Levofloxacin and moxifloxacin are "respiratory fluoroquinolones" with excellent anti-pneumococcal activity - used for community-acquired pneumonia, sinusitis, and bronchitis.*

---

**Q48.** Ciprofloxacin absorption is reduced by concurrent administration of:

A) Water
B) Antacids containing aluminum or magnesium
C) Proton pump inhibitors
D) H2 blockers

**Answer: B**
*Fluoroquinolones form chelates with divalent/trivalent cations (Mg2+, Al3+, Ca2+, Fe2+, Zn2+), reducing absorption by 50-90%. Antacids, sucralfate, zinc supplements, and dairy products should be avoided within 2 hours.*

---

**Q49.** Which serious CNS adverse effect can fluoroquinolones cause?

A) Parkinsonism
B) Seizures and psychosis (especially in elderly)
C) Cerebellar ataxia
D) Peripheral neuropathy only

**Answer: B**
*Fluoroquinolones inhibit GABA-A receptors, which can cause CNS excitation, seizures, confusion, and psychosis - especially in elderly patients and those with CNS disorders.*

---

**Q50.** Moxifloxacin should NOT be used for urinary tract infections because:

A) It is nephrotoxic
B) It has poor urinary excretion (primarily hepatic elimination)
C) It causes renal calculi
D) It increases serum creatinine

**Answer: B**
*Moxifloxacin is eliminated primarily via hepatic metabolism and fecal excretion. It does NOT achieve adequate urinary concentrations - use ciprofloxacin or levofloxacin for UTI.*

---

**Q51.** Which serious adverse effect was added to FDA Black Box Warning for fluoroquinolones in 2016?

A) Hepatotoxicity
B) Peripheral neuropathy and CNS effects (disabling and potentially irreversible)
C) Hemolytic anemia
D) Pulmonary fibrosis

**Answer: B**
*The FDA strengthened the black box warning in 2016 to include potentially disabling and irreversible serious adverse effects including peripheral neuropathy, CNS effects, tendinitis/rupture, and muscle weakness (in myasthenia gravis).*

---

## SECTION 7: SULFONAMIDES & TRIMETHOPRIM

**Q52.** What is the mechanism of action of sulfonamides?

A) Inhibit dihydrofolate reductase (DHFR)
B) Competitive inhibitor of dihydropteroate synthase, blocking folic acid synthesis
C) Inhibit thymidylate synthase
D) Inhibit cell wall synthesis

**Answer: B**
*Sulfonamides are structural analogs of para-aminobenzoic acid (PABA). They competitively inhibit dihydropteroate synthase, preventing bacterial synthesis of dihydrofolic acid.*

---

**Q53.** What is the mechanism of action of trimethoprim?

A) Inhibits dihydropteroate synthase
B) Inhibits bacterial dihydrofolate reductase (DHFR), blocking THF synthesis
C) Inhibits RNA polymerase
D) Inhibits DNA gyrase

**Answer: B**
*Trimethoprim inhibits bacterial DHFR with ~50,000x higher affinity for bacterial vs. human DHFR, blocking conversion of dihydrofolate to tetrahydrofolate (THF - essential for purine/thymidine synthesis).*

---

**Q54.** Trimethoprim-sulfamethoxazole (TMP-SMX) is the drug of choice for:

A) Pseudomonas aeruginosa infections
B) Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment
C) MRSA bacteremia
D) Anaerobic infections

**Answer: B**
*TMP-SMX is first-line for PCP treatment (high dose) and prophylaxis (low dose) in immunocompromised patients (HIV/AIDS, transplant). It also covers MSSA, E. coli UTI, and Nocardia.*

---

**Q55.** Sulfonamides are contraindicated in neonates because:

A) They cause gray baby syndrome
B) They displace bilirubin from albumin, causing kernicterus
C) They cause aplastic anemia in neonates
D) They are nephrotoxic in neonates

**Answer: B**
*Sulfonamides compete with bilirubin for albumin binding, releasing free bilirubin which crosses the immature blood-brain barrier causing kernicterus.*

---

**Q56.** A patient with G6PD deficiency is prescribed TMP-SMX. The main risk is:

A) Peripheral neuropathy
B) Hemolytic anemia
C) Aplastic anemia
D) Methemoglobinemia only

**Answer: B**
*Sulfonamides generate oxidative metabolites. In G6PD-deficient patients, RBCs cannot regenerate NADPH to neutralize oxidative stress, leading to hemolytic anemia.*

---

**Q57.** Which hypersensitivity reactions are associated with sulfonamides?

A) Anaphylaxis only
B) Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), serum sickness, SLE-like syndrome
C) Angioedema only
D) Contact dermatitis only

**Answer: B**
*Sulfonamides have a wide range of hypersensitivity reactions including SJS/TEN (potentially fatal), serum sickness, and SLE-like syndrome.*

---

## SECTION 8: LINCOSAMIDES (Clindamycin)

**Q58.** What is the mechanism of action of clindamycin?

A) Inhibits 30S ribosomal subunit
B) Binds to 50S ribosomal subunit, inhibiting peptide bond formation
C) Inhibits cell wall synthesis
D) Inhibits DNA replication

**Answer: B**
*Clindamycin binds to the 50S ribosomal subunit (23S rRNA, same binding site as macrolides and chloramphenicol), inhibiting peptidyl transferase and translocation.*

---

**Q59.** Clindamycin is particularly useful for:

A) Gram-negative aerobic infections
B) Anaerobic infections above the diaphragm, MRSA skin infections, and malaria
C) Pseudomonas infections
D) UTI caused by gram-negative rods

**Answer: B**
*Clindamycin is excellent for: (1) oral/dental anaerobes, (2) aspiration pneumonia, (3) MRSA skin/soft tissue infections (SSTI), (4) bone/joint infections, (5) toxin suppression in necrotizing fasciitis, and (6) Plasmodium falciparum malaria (with quinine).*

---

**Q60.** The MOST dangerous adverse effect of clindamycin is:

A) Nephrotoxicity
B) Pseudomembranous colitis (C. difficile-associated disease)
C) Ototoxicity
D) QT prolongation

**Answer: B**
*Clindamycin has one of the highest risks of C. difficile-associated diarrhea (CDAD/pseudomembranous colitis) among all antibiotics - related to its excellent anaerobic coverage disrupting the normal colonic flora.*

---

**Q61.** Clindamycin is used as an alternative to penicillin in patients with penicillin allergy for which condition?

A) Community-acquired pneumonia
B) Streptococcal pharyngitis and dental infections
C) Meningitis
D) Gram-negative UTI

**Answer: B**
*Clindamycin is a first-line alternative for penicillin-allergic patients with streptococcal pharyngitis, dental infections, and prophylaxis before dental procedures in those with cardiac risk.*

---

## SECTION 9: CHLORAMPHENICOL

**Q62.** What is the mechanism of action of chloramphenicol?

A) Inhibits 30S ribosomal subunit
B) Binds to 50S ribosomal subunit, inhibiting peptidyl transferase
C) Disrupts cell membrane
D) Inhibits RNA polymerase

**Answer: B**
*Chloramphenicol binds to the 50S ribosomal subunit (23S rRNA) and inhibits peptidyl transferase, preventing peptide bond formation.*

---

**Q63.** "Gray baby syndrome" is an adverse effect of chloramphenicol seen in neonates. What causes it?

A) Displacement of bilirubin from albumin
B) Immature hepatic glucuronidation leads to drug accumulation, causing cardiovascular collapse
C) Inhibition of mitochondrial protein synthesis
D) Hemolytic anemia

**Answer: B**
*Neonates lack adequate hepatic UDP-glucuronosyltransferase to conjugate chloramphenicol. Toxic levels accumulate causing gray skin color, vomiting, flaccidity, hypothermia, and cardiovascular collapse.*

---

**Q64.** The most feared hematological toxicity of chloramphenicol is:

A) Hemolytic anemia (dose-dependent)
B) Aplastic anemia (idiosyncratic, not dose-dependent)
C) Thrombocytopenia
D) Neutropenia

**Answer: B**
*Chloramphenicol causes two types of bone marrow suppression: (1) reversible dose-dependent suppression and (2) irreversible idiosyncratic aplastic anemia (~1:25,000-40,000) which is often fatal.*

---

**Q65.** Chloramphenicol is still used as the drug of choice for:

A) MRSA infections in developed countries
B) Bacterial meningitis in penicillin/cephalosporin-allergic patients in resource-limited settings, and typhoid fever
C) UTI caused by E. coli
D) Pseudomonas infections

**Answer: B**
*Despite its toxicity, chloramphenicol remains valuable in resource-limited settings for typhoid fever, H. influenzae meningitis, and as a last resort for rickettsial diseases.*

---

## SECTION 10: RIFAMYCINS (Rifampin)

**Q66.** What is the mechanism of action of rifampin?

A) Inhibits bacterial DNA gyrase
B) Inhibits bacterial DNA-dependent RNA polymerase (beta subunit)
C) Inhibits 30S ribosomal subunit
D) Inhibits cell wall synthesis

**Answer: B**
*Rifampin binds specifically to the beta-subunit of bacterial DNA-dependent RNA polymerase, inhibiting RNA synthesis (transcription). Human RNA polymerase has much lower affinity.*

---

**Q67.** Rifampin is used primarily for:

A) Gram-negative pneumonia
B) Tuberculosis (in combination), leprosy, and prophylaxis of N. meningitidis and H. influenzae contacts
C) MRSA bacteremia (as monotherapy)
D) Clostridium difficile colitis

**Answer: B**
*Rifampin is a cornerstone of TB treatment (RIPE: Rifampin, Isoniazid, Pyrazinamide, Ethambutol). It is also used for leprosy, and chemoprophylaxis for meningococcal and H. influenzae contacts.*

---

**Q68.** A major concern with rifampin therapy is its drug interaction profile. What is the mechanism?

A) It inhibits CYP450 enzymes
B) It is a potent inducer of CYP3A4, CYP2C9, and P-glycoprotein
C) It displaces drugs from plasma protein binding
D) It increases renal drug excretion

**Answer: B**
*Rifampin is one of the most potent CYP450 enzyme inducers known. It dramatically increases metabolism of warfarin, oral contraceptives, antiretrovirals, methadone, cyclosporine, corticosteroids, and many others.*

---

**Q69.** A patient on rifampin reports their urine, tears, and sweat turned orange-red. This is:

A) A sign of hepatotoxicity
B) Harmless discoloration of body fluids - patients should be counseled
C) Hemoglobinuria
D) Sign of drug toxicity requiring discontinuation

**Answer: B**
*Rifampin (and rifabutin) harmlessly discolor all body secretions (urine, tears, sweat, saliva, sputum, feces, breast milk) orange-red. Patients should be counseled to prevent alarm, and contact lenses may be stained permanently.*

---

**Q70.** Rifampin monotherapy is avoided in TB treatment because:

A) It is ineffective as a single agent
B) Resistance develops extremely rapidly (single-step mutations) when used alone
C) It is too nephrotoxic when used alone
D) It requires combination for absorption

**Answer: B**
*Rifampin resistance develops very rapidly (1 in 10^8 organisms) through single-point mutations in the rpoB gene encoding the beta subunit of RNA polymerase. Combination therapy prevents emergence of resistant mutants.*

---

## SECTION 11: NITROIMIDAZOLES (Metronidazole, Tinidazole)

**Q71.** What is the mechanism of action of metronidazole?

A) Inhibits cell wall synthesis
B) Reduced by anaerobic organisms to reactive intermediates that damage DNA
C) Inhibits 50S ribosomal subunit
D) Inhibits RNA polymerase

**Answer: B**
*Metronidazole is a prodrug. In anaerobic/microaerophilic organisms, it is reduced by ferredoxin/nitroreductase, generating cytotoxic free radical intermediates that cause DNA strand breaks.*

---

**Q72.** Metronidazole is the drug of choice for:

A) MRSA infections
B) Anaerobic infections (intra-abdominal, pelvic), C. difficile colitis, Trichomonas vaginalis, Giardia, and bacterial vaginosis
C) Pseudomonas aeruginosa
D) Gram-positive aerobic infections

**Answer: B**
*Metronidazole covers anaerobes (Bacteroides, Clostridium), protozoa (Giardia, Trichomonas, Entamoeba), and is used for C. difficile colitis (though oral vancomycin/fidaxomicin are now preferred).*

---

**Q73.** The most significant drug interaction with metronidazole is:

A) Increased effect of rifampin
B) Disulfiram-like reaction with alcohol
C) Decreased warfarin effect
D) QT prolongation with macrolides

**Answer: B**
*Metronidazole inhibits aldehyde dehydrogenase, causing accumulation of acetaldehyde when alcohol is consumed (disulfiram-like reaction: flushing, tachycardia, nausea, vomiting). Alcohol must be avoided during and 48 hours after therapy.*

---

**Q74.** Peripheral neuropathy from metronidazole is associated with:

A) Single short courses of therapy
B) Prolonged high-dose therapy
C) Topical application
D) Renal impairment

**Answer: B**
*Peripheral neuropathy (tingling, numbness) is associated with prolonged use (>2 weeks) or cumulative doses >24g. Seizures and encephalopathy can also occur.*

---

## SECTION 12: LINEZOLID & OXAZOLIDINONES

**Q75.** What is the mechanism of action of linezolid?

A) Inhibits 30S ribosomal subunit
B) Inhibits 50S ribosomal subunit by binding to 23S rRNA, preventing formation of the initiation complex
C) Inhibits RNA polymerase
D) Inhibits cell wall synthesis

**Answer: B**
*Linezolid binds to 23S rRNA of the 50S subunit, inhibiting formation of the 70S initiation complex - a unique mechanism that prevents cross-resistance with other protein synthesis inhibitors.*

---

**Q76.** Linezolid is indicated for:

A) Gram-negative pneumonia and UTI
B) MRSA and VRE infections
C) Pseudomonas aeruginosa bacteremia
D) C. difficile colitis

**Answer: B**
*Linezolid is FDA-approved for MRSA infections (nosocomial pneumonia, skin/soft tissue) and VRE infections when other options fail.*

---

**Q77.** A patient on linezolid for 6 weeks develops thrombocytopenia. What is the MOST likely cause?

A) Allergic reaction
B) Myelosuppression (dose and duration-dependent) - inhibition of mitochondrial protein synthesis
C) Autoimmune thrombocytopenia
D) Splenic sequestration

**Answer: B**
*Linezolid inhibits mitochondrial ribosomes (which resemble bacterial 70S ribosomes), causing myelosuppression (thrombocytopenia, anemia, neutropenia) with prolonged use (>2 weeks). CBC monitoring is essential.*

---

**Q78.** Linezolid is a monoamine oxidase inhibitor (MAOI). This means concurrent use with which drugs carries risk of serotonin syndrome?

A) Penicillins
B) SSRIs, SNRIs, TCAs, meperidine, dextromethorphan
C) Beta-blockers
D) Statins

**Answer: B**
*Linezolid inhibits MAO-A and MAO-B. Concurrent use with serotonergic drugs (SSRIs, SNRIs, tramadol, meperidine, dextromethorphan) can cause serotonin syndrome (hyperthermia, rigidity, clonus, autonomic instability).*

---

## SECTION 13: DAPTOMYCIN

**Q79.** What is the mechanism of action of daptomycin?

A) Inhibits cell wall synthesis
B) Inserts into bacterial cell membrane, causing depolarization and ion leakage
C) Inhibits 50S ribosomal subunit
D) Inhibits DNA gyrase

**Answer: B**
*Daptomycin is a lipopeptide antibiotic. It inserts its lipid tail into the gram-positive bacterial membrane, causing rapid membrane depolarization, loss of membrane potential, and cell death.*

---

**Q80.** Daptomycin should NOT be used for pneumonia. Why?

A) Poor tissue penetration
B) Inactivated by pulmonary surfactant
C) Severe respiratory adverse effects
D) Ineffective against Streptococcus pneumoniae

**Answer: B**
*Daptomycin binds avidly to pulmonary surfactant, which inactivates it. It should not be used for lung infections despite good activity against gram-positives.*

---

**Q81.** The most important adverse effect to monitor with daptomycin is:

A) Nephrotoxicity
B) Skeletal muscle toxicity (myopathy) - elevated CPK
C) Hepatotoxicity
D) QT prolongation

**Answer: B**
*Daptomycin can cause myopathy and rhabdomyolysis. CPK levels should be monitored weekly. Statins should be temporarily discontinued during daptomycin therapy.*

---

## SECTION 14: POLYMYXINS (Colistin/Polymyxin E, Polymyxin B)

**Q82.** What is the mechanism of action of polymyxins (colistin)?

A) Inhibit protein synthesis
B) Bind to lipopolysaccharide (LPS) of gram-negative cell membrane, disrupting membrane integrity
C) Inhibit DNA replication
D) Inhibit cell wall cross-linking

**Answer: B**
*Polymyxins are cyclic lipopeptides that bind to the phosphate groups of LPS on the gram-negative outer membrane, displacing Mg2+ and Ca2+, disrupting membrane integrity, and causing leakage of cell contents.*

---

**Q83.** Polymyxins are used as "last-resort" antibiotics for:

A) MRSA and VRE infections
B) Carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa (MDR gram-negative)
C) Streptococcal infections
D) Anaerobic infections

**Answer: B**
*Polymyxins (colistin, polymyxin B) are reserved for MDR/XDR gram-negative infections (carbapenem-resistant Klebsiella, Acinetobacter, Pseudomonas) when no other options exist.*

---

**Q84.** The major dose-limiting toxicity of colistin is:

A) Ototoxicity
B) Nephrotoxicity (acute tubular necrosis)
C) Hepatotoxicity
D) Cardiotoxicity

**Answer: B**
*Nephrotoxicity (occurring in 30-60% of patients) is the primary dose-limiting toxicity of colistin, manifested as elevated creatinine and acute tubular necrosis.*

---

## SECTION 15: NITROFURANTOIN

**Q85.** Nitrofurantoin is used for:

A) Systemic gram-negative infections
B) Uncomplicated lower urinary tract infections (cystitis)
C) Pyelonephritis
D) Gram-positive bacteremia

**Answer: B**
*Nitrofurantoin achieves high concentrations only in urine, making it effective only for uncomplicated lower UTI (cystitis). It should NOT be used for pyelonephritis (requires systemic levels).*

---

**Q86.** Nitrofurantoin is contraindicated in patients with:

A) Hypertension
B) Renal insufficiency (CrCl < 30 mL/min) and G6PD deficiency
C) Liver disease only
D) Diabetes mellitus

**Answer: B**
*In renal insufficiency, nitrofurantoin fails to achieve adequate urinary concentrations (ineffective) while potentially accumulating systemically (toxic). In G6PD deficiency, it causes hemolytic anemia.*

---

**Q87.** Long-term nitrofurantoin prophylaxis can cause which serious pulmonary reaction?

A) Asthma exacerbation
B) Pulmonary fibrosis (chronic) and acute hypersensitivity pneumonitis
C) Pneumothorax
D) Pulmonary edema

**Answer: B**
*Nitrofurantoin can cause: (1) acute hypersensitivity pneumonitis (reversible), and (2) chronic pulmonary fibrosis with prolonged use. Peripheral neuropathy is also a concern with long-term use.*

---

## SECTION 16: FOSFOMYCIN

**Q88.** What is the mechanism of action of fosfomycin?

A) Inhibits DNA gyrase
B) Inhibits MurA (enolpyruvyl transferase), the first step of peptidoglycan synthesis
C) Binds to 30S ribosomal subunit
D) Disrupts cell membrane

**Answer: B**
*Fosfomycin inhibits the enzyme MurA (UDP-N-acetylglucosamine enolpyruvyl transferase), which catalyzes the first committed step in cell wall (peptidoglycan) biosynthesis.*

---

**Q89.** A single oral dose of fosfomycin trometamol is used for:

A) Complicated pyelonephritis
B) Uncomplicated UTI in women (E. coli, Enterococcus faecalis)
C) MRSA bacteremia
D) Anaerobic infections

**Answer: B**
*Fosfomycin trometamol as a single 3g oral dose achieves high urinary concentrations and is approved for uncomplicated lower UTI, including those caused by ESBL-producing organisms and multidrug-resistant strains.*

---

## SECTION 17: ANTI-TB DRUGS (RIPE Therapy)

**Q90.** What is the mechanism of action of isoniazid (INH)?

A) Inhibits RNA polymerase
B) Inhibits synthesis of mycolic acids (essential cell wall components) by inhibiting InhA (enoyl-ACP reductase) after activation by KatG
C) Inhibits 30S ribosomal subunit
D) Inhibits DNA gyrase

**Answer: B**
*INH is a prodrug activated by mycobacterial catalase-peroxidase (KatG) to an isonicotinoyl radical, which inhibits InhA (enoyl-ACP reductase), blocking mycolic acid biosynthesis - unique to mycobacteria.*

---

**Q91.** INH causes peripheral neuropathy due to its antagonism of:

A) Vitamin B12 (cobalamin)
B) Pyridoxine (vitamin B6) - INH complexes with B6
C) Folic acid
D) Niacin (vitamin B3)

**Answer: B**
*INH is structurally similar to pyridoxine and competes with its cofactor role. It causes relative B6 deficiency manifesting as peripheral neuropathy. Prophylactic pyridoxine (25-50 mg/day) is co-administered.*

---

**Q92.** Slow acetylators of INH have higher risk of:

A) Treatment failure due to lower drug levels
B) Peripheral neuropathy and hepatotoxicity due to accumulation
C) Drug resistance
D) Pulmonary reactions

**Answer: B**
*INH is metabolized by N-acetyltransferase (NAT2). Slow acetylators (~50% of Caucasians and African Americans) accumulate higher drug levels, increasing the risk of peripheral neuropathy and hepatotoxicity.*

---

**Q93.** Ethambutol's most important adverse effect is:

A) Hepatotoxicity
B) Optic neuritis (retrobulbar neuritis) - decreased visual acuity, red-green color blindness
C) Hyperuricemia
D) Peripheral neuropathy

**Answer: B**
*Ethambutol inhibits arabinosyltransferases involved in arabinoglycan synthesis. Its dose-dependent adverse effect is optic neuritis manifesting as decreased visual acuity and loss of red-green color discrimination. Baseline and periodic eye exams are needed.*

---

**Q94.** Pyrazinamide's most common adverse effect is:

A) Peripheral neuropathy
B) Hyperuricemia (inhibits urate excretion) and hepatotoxicity
C) Optic neuritis
D) Nephrotoxicity

**Answer: B**
*Pyrazinamide inhibits renal tubular secretion of urate, causing hyperuricemia (and potentially gout). It is also the most hepatotoxic first-line TB drug.*

---

**Q95.** The "short-course" standard TB treatment regimen is:

A) 9 months of INH + rifampin
B) 2 months RIPE (rifampin, INH, pyrazinamide, ethambutol) followed by 4 months rifampin + INH
C) 6 months of INH monotherapy
D) 12 months RIPE throughout

**Answer: B**
*Standard TB treatment: Initial phase - 2 months of RIPE (Rifampin + INH + Pyrazinamide + Ethambutol); Continuation phase - 4 months of Rifampin + INH. Total = 6 months (2RIPE/4RI).*

---

## SECTION 18: ANTIFUNGAL ANTIBIOTICS (Amphotericin B)

**Q96.** What is the mechanism of action of amphotericin B?

A) Inhibits fungal cell wall (glucan) synthesis
B) Binds to ergosterol in fungal cell membrane, creating pores causing leakage
C) Inhibits fungal cytochrome P450 (CYP51/lanosterol demethylase)
D) Inhibits fungal DNA synthesis

**Answer: B**
*Amphotericin B binds selectively to ergosterol (present in fungal membranes, not human membranes which contain cholesterol), creating membrane pores that cause electrolyte leakage and cell death.*

---

**Q97.** The dose-limiting toxicity of conventional amphotericin B deoxycholate is:

A) Hepatotoxicity
B) Nephrotoxicity (renal tubular acidosis, azotemia, hypokalemia, hypomagnesemia)
C) Myelosuppression
D) QT prolongation

**Answer: B**
*Amphotericin B causes nephrotoxicity in up to 80% of patients through renal vasoconstriction and direct tubular toxicity. Lipid formulations (liposomal amphotericin B - AmBisome) were developed to reduce nephrotoxicity.*

---

**Q98.** "Shake and bake" phenomenon associated with amphotericin B refers to:

A) A drug interaction with azoles
B) Infusion-related reactions (fever, chills, rigors, hypotension) occurring during IV infusion
C) A sign of hepatotoxicity
D) Neurotoxicity

**Answer: B**
*Amphotericin B frequently causes infusion-related reactions (fever, chills/rigors, headache, hypotension, nausea) during administration. Premedication with acetaminophen, diphenhydramine, and meperidine (for rigors) reduces these reactions.*

---

## SECTION 19: AZOLE ANTIFUNGALS

**Q99.** What is the mechanism of action of azole antifungals (fluconazole, itraconazole, voriconazole, posaconazole)?

A) Bind to ergosterol in fungal membrane
B) Inhibit fungal CYP51 (lanosterol 14-alpha-demethylase), blocking ergosterol synthesis
C) Inhibit fungal cell wall glucan synthesis
D) Inhibit fungal DNA polymerase

**Answer: B**
*Azoles inhibit the fungal enzyme lanosterol 14-alpha-demethylase (a CYP51 enzyme), blocking conversion of lanosterol to ergosterol, depleting the fungal membrane of its essential sterol.*

---

**Q100.** Which azole is the drug of choice for Aspergillus infections?

A) Fluconazole
B) Ketoconazole
C) Voriconazole
D) Clotrimazole

**Answer: C**
*Voriconazole is first-line therapy for invasive aspergillosis. Fluconazole lacks Aspergillus activity. Isavuconazole and posaconazole are alternatives.*

---

## SECTION 20: ECHINOCANDINS

**Q101.** What is the mechanism of action of echinocandins (caspofungin, micafungin, anidulafungin)?

A) Inhibit ergosterol synthesis
B) Inhibit beta-1,3-glucan synthase, disrupting fungal cell wall synthesis
C) Bind to ergosterol and create membrane pores
D) Inhibit fungal protein synthesis

**Answer: B**
*Echinocandins are the ONLY antifungals that target the fungal cell wall. They inhibit beta-1,3-glucan synthase, an enzyme absent in mammalian cells, making them highly selective with a favorable safety profile.*

---

## SECTION 21: ANTIVIRALS (High-Yield Antibiotic-Related)

**Q102.** Acyclovir's mechanism of action involves:

A) Inhibiting viral RNA polymerase
B) Phosphorylation by viral thymidine kinase, then inhibiting viral DNA polymerase as a chain terminator
C) Blocking viral attachment to host cells
D) Inhibiting viral protease

**Answer: B**
*Acyclovir is monophosphorylated by HSV thymidine kinase (viral selectivity), then di- and triphosphorylated by cellular kinases. Acyclovir-TP competitively inhibits viral DNA polymerase and acts as a chain terminator.*

---

## SECTION 22: RESISTANCE MECHANISMS

**Q103.** The primary mechanism of aminoglycoside resistance is:

A) Decreased cell wall permeability
B) Enzymatic modification (acetylation, phosphorylation, adenylylation) of aminoglycosides by transferases
C) Modification of ribosomal target
D) Efflux pumps only

**Answer: B**
*Aminoglycoside-modifying enzymes (acetyltransferases - AAC, phosphotransferases - APH, nucleotidyltransferases - ANT) are the predominant resistance mechanism, chemically inactivating the drug before it reaches the ribosome.*

---

**Q104.** MRSA resistance to beta-lactams is due to:

A) Beta-lactamase production
B) Acquisition of mecA gene encoding PBP2a, an altered PBP with low beta-lactam affinity
C) Efflux pumps
D) Decreased outer membrane permeability

**Answer: B**
*MRSA carries the mecA gene (on SCCmec element) encoding PBP2a, an altered penicillin-binding protein with very low affinity for all beta-lactams, conferring broad resistance.*

---

**Q105.** ESBL (Extended-Spectrum Beta-Lactamase) producing organisms are resistant to:

A) Aminoglycosides only
B) All penicillins and cephalosporins (but generally susceptible to carbapenems)
C) All antibiotics including carbapenems
D) Only first-generation cephalosporins

**Answer: B**
*ESBLs hydrolyze the beta-lactam ring of most penicillins and cephalosporins (including 3rd/4th generation). Carbapenems are generally stable to ESBLs and remain treatment of choice, unless also carbapenem-resistant (KPC, NDM).*

---

**Q106.** Efflux pump overexpression as a resistance mechanism is MOST clinically important for:

A) Vancomycin
B) Tetracyclines and fluoroquinolones
C) Aminoglycosides
D) Beta-lactams

**Answer: B**
*Efflux pumps (e.g., Tet efflux pumps for tetracyclines; MexAB-OprM in Pseudomonas for fluoroquinolones) are a major resistance mechanism, actively pumping drugs out of bacteria.*

---

**Q107.** "Tolerance" versus "resistance" in antibiotics differs in that:

A) Tolerant organisms have MICs within the susceptible range but are not killed (MBC>>MIC)
B) Tolerant organisms have elevated MICs
C) Tolerant organisms produce beta-lactamases
D) There is no difference

**Answer: A**
*Tolerant bacteria are inhibited (static) by antibiotic concentrations within the susceptible MIC range but not killed. The minimum bactericidal concentration (MBC) is much higher than the MIC. Seen in biofilms and stationary-phase bacteria.*

---

## SECTION 23: PHARMACOKINETICS & PHARMACODYNAMICS

**Q108.** Which antibiotic class exhibits TIME-dependent killing (efficacy depends on time above MIC)?

A) Aminoglycosides
B) Fluoroquinolones
C) Beta-lactams (penicillins, cephalosporins)
D) Metronidazole

**Answer: C**
*Beta-lactams exhibit time-dependent killing - efficacy correlates with the percent of the dosing interval that drug concentrations remain above the MIC (T>MIC). They have minimal concentration-dependent killing effect.*

---

**Q109.** Which antibiotic class shows CONCENTRATION-dependent killing?

A) Penicillins
B) Cephalosporins
C) Aminoglycosides and fluoroquinolones
D) Carbapenems

**Answer: C**
*Aminoglycosides and fluoroquinolones kill bacteria in a concentration-dependent manner - the higher the peak concentration relative to MIC (Cmax/MIC), the greater and faster the kill. This justifies once-daily aminoglycoside dosing.*

---

**Q110.** The post-antibiotic effect (PAE) is MOST pronounced with:

A) Penicillins
B) Aminoglycosides and fluoroquinolones
C) Cephalosporins
D) Vancomycin

**Answer: B**
*Aminoglycosides and fluoroquinolones exhibit a significant post-antibiotic effect (PAE) - continued suppression of bacterial growth after drug concentration falls below MIC. This supports once-daily dosing regimens.*

---

**Q111.** Renally dose-adjusted antibiotics include all EXCEPT:

A) Aminoglycosides
B) Vancomycin
C) Azithromycin
D) Cephalosporins (most)

**Answer: C**
*Azithromycin is primarily eliminated through biliary/fecal excretion and does NOT require dose adjustment in renal impairment. All others listed require dose adjustment with reduced renal function.*

---

**Q112.** A patient with severe hepatic impairment requires antibiotic therapy. Which antibiotic requires the MOST caution due to hepatic elimination?

A) Vancomycin (renally eliminated)
B) Metronidazole (hepatically metabolized)
C) Aminoglycosides (renally eliminated)
D) Aztreonam (renally eliminated)

**Answer: B**
*Metronidazole is extensively metabolized by the liver. Severe hepatic impairment reduces its clearance, leading to accumulation and increased risk of CNS toxicity. Dose reduction is recommended.*

---

## SECTION 24: DRUG INTERACTIONS

**Q113.** Which combination is particularly synergistic against enterococcal endocarditis?

A) Vancomycin + rifampin
B) Ampicillin + gentamicin
C) Clindamycin + metronidazole
D) Ciprofloxacin + azithromycin

**Answer: B**
*Ampicillin (inhibits cell wall synthesis, facilitating aminoglycoside entry) + gentamicin (ribosomal inhibition) is a classic synergistic combination for serious enterococcal infections including endocarditis.*

---

**Q114.** Which antibiotic causes a disulfiram-like reaction with alcohol AND inhibits warfarin metabolism?

A) Azithromycin
B) Metronidazole (and certain cephalosporins like cefamandole, cefoperazone with MTT side chain)
C) Tetracycline
D) Vancomycin

**Answer: B**
*Metronidazole inhibits aldehyde dehydrogenase (disulfiram-like) and inhibits CYP2C9 (warfarin metabolism). Cephalosporins with the methylthiotetrazole (MTT) side chain also cause disulfiram-like reactions.*

---

**Q115.** Rifampin drastically reduces the efficacy of oral contraceptives by:

A) Directly binding to estrogen
B) Inducing CYP3A4, accelerating estrogen and progestin metabolism
C) Inhibiting GI absorption of contraceptive pills
D) Increasing urinary excretion of contraceptive hormones

**Answer: B**
*Rifampin is a potent CYP3A4 inducer. It increases the metabolism of ethinylestradiol and progestins, potentially reducing contraceptive efficacy. Alternative or additional contraception is recommended.*

---

**Q116.** The bactericidal combination used for PCP treatment (high-dose TMP-SMX) commonly causes which electrolyte abnormality?

A) Hyponatremia
B) Hyperkalemia (trimethoprim blocks renal tubular potassium secretion)
C) Hypokalemia
D) Hypercalcemia

**Answer: B**
*Trimethoprim inhibits renal tubular potassium secretion (similar to amiloride), causing hyperkalemia, particularly with high-dose TMP-SMX (PCP treatment doses). Monitor potassium levels.*

---

## SECTION 25: SPECIAL CLINICAL SCENARIOS

**Q117.** A pregnant woman has a UTI. Which antibiotic is SAFE in all trimesters?

A) Tetracycline
B) Fluoroquinolones
C) Nitrofurantoin (use with caution near term) or cephalosporins
D) TMP-SMX (in first trimester due to folate antagonism)

**Answer: C**
*Cephalosporins are considered safe throughout pregnancy. Nitrofurantoin is safe in 1st/2nd trimester but avoided near term (hemolytic anemia risk). Tetracyclines, fluoroquinolones, and TMP-SMX (1st trimester) are avoided.*

---

**Q118.** A patient with penicillin allergy (anaphylaxis) needs coverage for gram-negative infections including Pseudomonas. The SAFEST beta-lactam choice is:

A) Cephalosporins (high cross-reactivity)
B) Carbapenems (moderate cross-reactivity)
C) Aztreonam (minimal cross-reactivity with penicillin)
D) Avoid all beta-lactams

**Answer: C**
*Aztreonam (monobactam) has virtually no cross-reactivity with penicillins because its unique monocyclic ring structure is unlike the bicyclic penicillin/cephalosporin structures.*

---

**Q119.** The first-line treatment for Clostridioides difficile infection (CDI) - non-severe is:

A) Metronidazole IV
B) Oral vancomycin or oral fidaxomicin
C) Oral clindamycin
D) IV metronidazole + oral vancomycin

**Answer: B**
*Per current IDSA/SHEA guidelines (2021), oral vancomycin or oral fidaxomicin (preferred - lower recurrence rate) are first-line for initial non-severe CDI. IV metronidazole is now relegated to adjunctive therapy when oral route is unavailable.*

---

**Q120.** A patient develops severe watery diarrhea after clindamycin therapy. Sigmoidoscopy shows yellowish plaques on the mucosa. Diagnosis and treatment?

A) Irritable bowel syndrome; reassurance
B) Pseudomembranous colitis due to C. difficile; oral vancomycin or fidaxomicin
C) Salmonella colitis; ciprofloxacin
D) Ischemic colitis; supportive care

**Answer: B**
*Yellowish plaques (pseudomembranes) on sigmoidoscopy are pathognomonic of C. difficile pseudomembranous colitis. Clindamycin is the classic precipitant. Treat with oral vancomycin or fidaxomicin.*

---

**Q121.** Drug of choice for Chlamydia trachomatis urethritis/cervicitis is:

A) Penicillin
B) Doxycycline (7 days) or azithromycin (1g single dose)
C) Ciprofloxacin
D) Metronidazole

**Answer: B**
*CDC guidelines recommend doxycycline 100mg BID x 7 days (preferred) or azithromycin 1g single dose for uncomplicated Chlamydia. Doxycycline is preferred due to higher efficacy data.*

---

**Q122.** Prophylaxis for meningococcal contacts (close household contacts) uses:

A) Penicillin G IM
B) Rifampin x 2 days, or ciprofloxacin single dose, or ceftriaxone single dose IM
C) Vancomycin
D) Azithromycin

**Answer: B**
*Post-exposure chemoprophylaxis for N. meningitidis contacts: rifampin 600mg BID x 2 days (not in pregnancy), or ciprofloxacin 500mg single dose, or ceftriaxone 250mg IM single dose.*

---

**Q123.** A patient with CAP (community-acquired pneumonia) who is a healthy outpatient (no comorbidities) should receive:

A) IV vancomycin + piperacillin-tazobactam
B) Amoxicillin alone, or azithromycin/doxycycline alone
C) Meropenem + colistin
D) Rifampin + INH

**Answer: B**
*IDSA guidelines for CAP in healthy outpatients without recent antibiotics: amoxicillin, doxycycline, or a macrolide (azithromycin). Respiratory fluoroquinolones are reserved for comorbid patients.*

---

**Q124.** Which antibiotic is the drug of choice for Lyme disease (Borrelia burgdorferi)?

A) Vancomycin
B) Doxycycline (oral, for early localized/disseminated); IV ceftriaxone for neurological/cardiac Lyme
C) Ciprofloxacin
D) Metronidazole

**Answer: B**
*Doxycycline 100mg BID x 10-21 days is first-line for early Lyme disease. Amoxicillin and cefuroxime are alternatives. IV ceftriaxone is used for CNS Lyme disease (meningitis, encephalitis).*

---

**Q125.** The antibiotic of choice for syphilis (Treponema pallidum) at all stages is:

A) Doxycycline
B) Benzathine penicillin G
C) Ceftriaxone
D) Azithromycin

**Answer: B**
*Benzathine penicillin G is the only recommended treatment for all stages of syphilis, including congenital. Doxycycline is an alternative for non-pregnant penicillin-allergic patients in primary/secondary syphilis.*

---

## SECTION 26: ANTIBIOTIC PROPHYLAXIS

**Q126.** Standard prophylaxis for prevention of infective endocarditis (IE) before dental procedures in high-risk patients is:

A) Vancomycin IV
B) Amoxicillin 2g PO 30-60 minutes before procedure
C) Clindamycin 600mg PO (now REMOVED from AHA guidelines for routine use)
D) Cephalexin 500mg

**Answer: B**
*AHA 2021 guidelines: amoxicillin 2g PO 30-60 min before dental procedures for high-risk patients (prosthetic valves, prior IE, specific CHD). If penicillin-allergic: cephalexin, azithromycin, or doxycycline.*

---

**Q127.** Surgical prophylaxis should be administered:

A) 24 hours before surgery
B) Within 60 minutes before skin incision (30 minutes for fluoroquinolones/vancomycin)
C) Immediately after surgery
D) For 7 days postoperatively

**Answer: B**
*Optimal timing is within 60 minutes before skin incision (within 30 minutes for fluoroquinolones/vancomycin) to ensure adequate tissue levels at the time of incision.*

---

## SECTION 27: MISCELLANEOUS HIGH-YIELD

**Q128.** Which antibiotic is associated with causing tendinopathy and tendon rupture, especially involving the Achilles tendon?

A) Amoxicillin
B) Fluoroquinolones (ciprofloxacin, levofloxacin)
C) Doxycycline
D) Vancomycin

**Answer: B**
*Fluoroquinolone-associated tendinopathy/rupture is a Black Box Warning. Risk is highest in patients >60 years, on corticosteroids, or with renal transplant.*

---

**Q129.** "Tooth discoloration in children" is a classic adverse effect associated with which antibiotic?

A) Amoxicillin
B) Tetracyclines
C) Erythromycin
D) Clindamycin

**Answer: B**
*Tetracyclines chelate calcium in developing enamel and bone, causing permanent yellowish-brown discoloration and enamel hypoplasia in children under 8 years.*

---

**Q130.** Chloramphenicol is known to cause which severe hematological toxicity?

A) Hemolytic anemia
B) Aplastic anemia (idiosyncratic) and dose-dependent bone marrow suppression
C) Thrombocytopenia only
D) Polycythemia vera

**Answer: B**
*Chloramphenicol causes two distinct marrow effects: dose-dependent reversible suppression (related to mitochondrial protein synthesis inhibition) and rare (1:25,000-40,000) fatal idiosyncratic aplastic anemia.*

---

**Q131.** A patient on isoniazid develops hepatitis. Predisposing factors include:

A) Age under 20 and female sex
B) Age over 35, alcoholism, pre-existing liver disease, and slow acetylator phenotype
C) Renal impairment
D) Concurrent vitamin B6 supplementation

**Answer: B**
*INH hepatotoxicity risk increases with age (>35), alcohol use, pre-existing liver disease, and slow acetylator phenotype (accumulate more hydrazine - a hepatotoxic metabolite).*

---

**Q132.** The antibiotic most likely to cause photosensitivity and should be avoided in patients with strong sun exposure is:

A) Amoxicillin
B) Doxycycline
C) Vancomycin
D) Metronidazole

**Answer: B**
*Doxycycline (and other tetracyclines) is well-known for causing photosensitivity (phototoxic reaction). Patients should use sunscreen and protective clothing.*

---

**Q133.** A patient receiving gentamicin for 10 days develops tinnitus and high-frequency hearing loss. The mechanism is:

A) Direct cochlear inflammation
B) Drug accumulation in the endolymph/perilymph causing oxidative damage to cochlear hair cells
C) Auditory nerve demyelination
D) Middle ear infection

**Answer: B**
*Aminoglycosides accumulate in the endolymph and perilymph. They generate reactive oxygen species that destroy outer hair cells in the basal cochlea (responsible for high-frequency hearing), causing irreversible sensorineural hearing loss.*

---

**Q134.** Which antibiotic causes "fanconi syndrome" and renal tubular acidosis?

A) Gentamicin
B) Outdated (expired) tetracyclines
C) Colistin
D) Vancomycin

**Answer: B**
*Expired/degraded tetracyclines (particularly tetracycline hydrochloride) produce toxic degradation products (anhydrotetracycline, epianhydrotetracycline) that cause Fanconi syndrome (renal proximal tubular dysfunction) and metabolic acidosis.*

---

**Q135.** QT prolongation and risk of torsades de pointes is associated with which antibiotics?

A) Penicillins and cephalosporins
B) Macrolides (erythromycin, azithromycin), fluoroquinolones (moxifloxacin), and azole antifungals
C) Aminoglycosides and tetracyclines
D) Rifampin and INH

**Answer: B**
*Macrolides, fluoroquinolones, and azole antifungals can prolong the QT interval. Risk is compounded by hypokalemia, hypomagnesemia, bradycardia, or concomitant use of other QT-prolonging drugs.*

---

## SECTION 28: TARGETED/ADVANCED QUESTIONS

**Q136.** Linezolid's unique mechanism - blocking the 70S initiation complex - confers an important clinical advantage:

A) It has broader gram-negative coverage than vancomycin
B) No cross-resistance with other protein synthesis inhibitors (macrolides, aminoglycosides, tetracyclines)
C) It is safe in neonates
D) It has zero drug interactions

**Answer: B**
*Because linezolid binds to a unique site and blocks a different step (initiation complex formation), organisms resistant to macrolides, chloramphenicol, aminoglycosides, and tetracyclines remain susceptible.*

---

**Q137.** A patient with a prosthetic joint infection due to MRSA is treated with a combination. Why is rifampin included?

A) To reduce the risk of C. difficile
B) Rifampin penetrates biofilm and kills slow-growing/biofilm-embedded MRSA; combination prevents rapid rifampin resistance
C) Rifampin is active against gram-negatives
D) Rifampin has the lowest nephrotoxicity

**Answer: B**
*Rifampin penetrates biofilm and is active against stationary-phase bacteria (important in prosthetic device infections). It must always be combined to prevent rapid development of resistance (single-step mutations).*

---

**Q138.** The "Eagle effect" (inoculum effect) with beta-lactams describes:

A) Paradoxical killing of bacteria at very low drug concentrations
B) Paradoxical DECREASED killing at very HIGH inocula of bacteria, as stationary-phase organisms stop expressing PBPs
C) Enhanced killing in the post-antibiotic period
D) Loss of efficacy due to protein binding

**Answer: B**
*The Eagle effect describes paradoxical antibiotic tolerance at high bacterial density, where stationary-phase organisms cease cell wall synthesis, rendering beta-lactams (which require active PBP synthesis) less effective.*

---

**Q139.** Ceftazidime-avibactam is used for:

A) MRSA infections
B) KPC, OXA-48 and AmpC beta-lactamase-producing gram-negative organisms (carbapenem-resistant Enterobacterales)
C) Fungal infections
D) C. difficile infections

**Answer: B**
*Avibactam is a non-beta-lactam beta-lactamase inhibitor that inhibits KPC, OXA-48, AmpC, and ESBL enzymes. Ceftazidime-avibactam is used for carbapenem-resistant Enterobacterales (CRE) and MDR Pseudomonas.*

---

**Q140.** Fidaxomicin is preferred over oral vancomycin for C. difficile because:

A) It is cheaper
B) It has a lower rate of recurrence due to minimal disruption of normal colonic flora and narrow spectrum (C. diff only)
C) It can be given IV
D) It covers gram-negative organisms too

**Answer: B**
*Fidaxomicin is a macrocyclic antibiotic with bactericidal activity against C. difficile and minimal activity against normal flora. Clinical trials show ~40% lower recurrence rates compared to vancomycin.*

---

**Q141.** The drug of choice for community-associated MRSA (CA-MRSA) skin and soft tissue infections (non-severe, outpatient) is:

A) IV vancomycin
B) TMP-SMX, doxycycline, or clindamycin (oral, based on susceptibility)
C) Linezolid IV
D) Piperacillin-tazobactam

**Answer: B**
*CA-MRSA SSTIs typically respond to outpatient oral agents: TMP-SMX (co-trimoxazole), doxycycline, or clindamycin (if D-zone test negative for inducible resistance). IV vancomycin is for severe/systemic infections.*

---

**Q142.** "Antibiotic stewardship" aims primarily to:

A) Reduce the cost of antibiotics only
B) Optimize antibiotic use to improve patient outcomes, reduce resistance, minimize adverse effects and C. difficile
C) Ensure antibiotics are available for all patients
D) Promote use of broad-spectrum antibiotics

**Answer: B**
*Antibiotic stewardship programs (ASPs) use evidence-based strategies (de-escalation, appropriate dosing, PK/PD optimization, rapid diagnostics) to improve outcomes, minimize selection pressure for resistance, and reduce CDI and adverse effects.*

---

**Q143.** Which test is used to detect inducible clindamycin resistance (D-zone test)?

A) Kirby-Bauer disk diffusion for clindamycin alone
B) D-zone test (disk induction test) - erythromycin disk placed near clindamycin disk; flattening of clindamycin zone (D-shape) indicates inducible MLSb resistance
C) MIC broth microdilution
D) PCR for erm genes only

**Answer: B**
*The D-zone test (double-disk diffusion) screens for inducible clindamycin resistance mediated by MLSb (methylase) genes. If D-shaped inhibition zone is seen, clindamycin should NOT be used despite apparent in-vitro susceptibility.*

---

**Q144.** Beta-lactam allergy cross-reactivity depends primarily on:

A) Molecular weight of the antibiotic
B) The R1 side chain structure (similar side chains = higher cross-reactivity)
C) Route of administration
D) Protein binding percentage

**Answer: B**
*Modern understanding shows that cross-reactivity between beta-lactams is primarily determined by the R1 side chain structure, not the beta-lactam ring. Cefazolin has a unique side chain with very low cross-reactivity with penicillin.*

---

**Q145.** A patient needs treatment for hospital-acquired pneumonia (HAP) caused by Acinetobacter baumannii resistant to all carbapenems. What is the BEST antibiotic option?

A) High-dose penicillin
B) Colistin (polymyxin E) ± carbapenem combination
C) Vancomycin
D) Clindamycin

**Answer: B**
*Carbapenem-resistant Acinetobacter baumannii (CRAB) is among the most difficult-to-treat nosocomial pathogens. Colistin (±rifampin, sulbactam, or carbapenem at high dose) remains a primary treatment option.*

---

## SECTION 29: PHARMACIST-FOCUSED CLINICAL PEARLS

**Q146.** A pharmacist reviewing medication profiles notes a patient on ciprofloxacin and theophylline. The concern is:

A) Ciprofloxacin decreases theophylline renal excretion
B) Ciprofloxacin inhibits CYP1A2, increasing theophylline levels and risk of seizures/arrhythmias
C) No significant interaction
D) Ciprofloxacin induces theophylline metabolism

**Answer: B**
*Ciprofloxacin is a significant CYP1A2 inhibitor. It inhibits theophylline metabolism, potentially doubling plasma levels, risking toxicity (seizures, arrhythmias). Theophylline levels must be monitored and dose reduced.*

---

**Q147.** A patient on warfarin is started on metronidazole for C. difficile. Expected INR change?

A) Decrease (metronidazole induces warfarin metabolism)
B) Increase (metronidazole inhibits CYP2C9, reducing warfarin S-enantiomer metabolism)
C) No change
D) Unpredictable - no interaction exists

**Answer: B**
*Metronidazole inhibits CYP2C9 (the primary enzyme metabolizing warfarin's more potent S-enantiomer), leading to elevated warfarin levels and increased bleeding risk. INR monitoring and warfarin dose reduction are needed.*

---

**Q148.** During medication reconciliation for a patient starting TB treatment (rifampin-containing), the pharmacist should alert the physician that which commonly used drug will have MARKEDLY reduced efficacy?

A) Metformin
B) Antiretrovirals (e.g., protease inhibitors, NNRTIs), oral contraceptives, warfarin, cyclosporine
C) Lisinopril
D) Beta-blockers

**Answer: B**
*Rifampin is the most potent CYP enzyme inducer in clinical practice. It dramatically reduces levels of antiretrovirals (protease inhibitors, NNRTIs), OCP hormones (contraceptive failure), warfarin (need dose escalation), cyclosporine, and many others.*

---

**Q149.** Therapeutic drug monitoring (TDM) is MOST important for which antibiotics to optimize efficacy and minimize toxicity?

A) Amoxicillin and cephalexin
B) Vancomycin (AUC/MIC targeting) and aminoglycosides (Cmax and trough)
C) Azithromycin and doxycycline
D) Clindamycin and metronidazole

**Answer: B**
*Vancomycin and aminoglycosides have narrow therapeutic indices with concentration-dependent toxicity. Vancomycin uses AUC24/MIC monitoring (target 400-600); aminoglycosides monitor Cmax (efficacy) and trough (toxicity).*

---

**Q150.** A patient taking an SSRI (sertraline) is prescribed linezolid for MRSA infection. The pharmacist should:

A) Dispense without concern - no interaction
B) Alert the prescriber - concurrent use risks serotonin syndrome; consider alternative for MRSA (vancomycin, daptomycin, TMP-SMX)
C) Reduce the SSRI dose
D) Administer pyridoxine to prevent the interaction

**Answer: B**
*Linezolid is a weak, non-selective MAOI. Concurrent use with SSRIs, SNRIs, or other serotonergic drugs can cause serotonin syndrome (life-threatening: hyperthermia, clonus, rigidity, autonomic instability). FDA contraindications exist for this combination unless no alternatives are available and patient is monitored in a facility.*

---

## ANSWER KEY SUMMARY

| Q | A | Q | A | Q | A | Q | A | Q | A |
|---|---|---|---|---|---|---|---|---|---|
| 1 | B | 31 | B | 61 | B | 91 | B | 121 | B |
| 2 | B | 32 | A | 62 | B | 92 | B | 122 | B |
| 3 | C | 33 | B | 63 | B | 93 | B | 123 | B |
| 4 | C | 34 | A | 64 | B | 94 | B | 124 | B |
| 5 | B | 35 | A | 65 | B | 95 | B | 125 | B |
| 6 | B | 36 | B | 66 | B | 96 | B | 126 | B |
| 7 | B | 37 | B | 67 | B | 97 | B | 127 | B |
| 8 | D | 38 | D | 68 | B | 98 | B | 128 | B |
| 9 | B | 39 | B | 69 | B | 99 | B | 129 | B |
| 10 | C | 40 | C | 70 | B | 100 | C | 130 | B |
| 11 | B | 41 | B | 71 | B | 101 | B | 131 | B |
| 12 | B | 42 | C | 72 | B | 102 | B | 132 | B |
| 13 | B | 43 | C | 73 | B | 103 | B | 133 | B |
| 14 | B | 44 | B | 74 | B | 104 | B | 134 | B |
| 15 | B | 45 | B | 75 | B | 105 | B | 135 | B |
| 16 | B | 46 | B | 76 | B | 106 | B | 136 | B |
| 17 | B | 47 | C | 77 | B | 107 | A | 137 | B |
| 18 | B | 48 | B | 78 | B | 108 | C | 138 | B |
| 19 | B | 49 | B | 79 | B | 109 | C | 139 | B |
| 20 | B | 50 | B | 80 | B | 110 | B | 140 | B |
| 21 | B | 51 | B | 81 | B | 111 | C | 141 | B |
| 22 | B | 52 | B | 82 | B | 112 | B | 142 | B |
| 23 | B | 53 | B | 83 | B | 113 | B | 143 | B |
| 24 | B | 54 | B | 84 | B | 114 | B | 144 | B |
| 25 | C | 55 | B | 85 | B | 115 | B | 145 | B |
| 26 | B | 56 | B | 86 | B | 116 | B | 146 | B |
| 27 | B | 57 | B | 87 | B | 117 | C | 147 | B |
| 28 | C | 58 | B | 88 | B | 118 | C | 148 | B |
| 29 | B | 59 | B | 89 | B | 119 | B | 149 | B |
| 30 | B | 60 | B | 90 | B | 120 | B | 150 | B |

---

## QUICK-REFERENCE: ANTIBIOTIC MECHANISMS

| Class | Target | Mechanism |
|-------|--------|-----------|
| Beta-lactams | PBPs (transpeptidase) | Inhibit peptidoglycan cross-linking |
| Vancomycin | D-Ala-D-Ala | Block transglycosylation/transpeptidation |
| Aminoglycosides | 30S ribosome | Misreading of mRNA; faulty proteins |
| Tetracyclines | 30S ribosome | Block aminoacyl-tRNA binding |
| Macrolides | 50S ribosome (23S rRNA) | Block translocation |
| Clindamycin | 50S ribosome (23S rRNA) | Inhibit peptidyl transferase |
| Chloramphenicol | 50S ribosome (23S rRNA) | Inhibit peptidyl transferase |
| Linezolid | 50S ribosome (23S rRNA) | Block 70S initiation complex |
| Fluoroquinolones | DNA gyrase / Topoisomerase IV | Inhibit DNA replication |
| Rifampin | RNA polymerase (beta subunit) | Inhibit transcription |
| Sulfonamides | Dihydropteroate synthase | Block folic acid synthesis |
| Trimethoprim | Dihydrofolate reductase (DHFR) | Block THF synthesis |
| Metronidazole | DNA | Free radical-induced DNA strand breaks |
| Daptomycin | Cell membrane | Depolarization via pore formation |
| Polymyxins | Cell membrane (LPS) | Membrane disruption; leakage |
| INH | InhA (enoyl-ACP reductase) | Block mycolic acid synthesis |
| Ethambutol | Arabinosyltransferase | Block arabinoglycan synthesis |
| Amphotericin B | Ergosterol | Membrane pores |
| Azoles | Lanosterol 14-alpha-demethylase (CYP51) | Block ergosterol synthesis |
| Echinocandins | Beta-1,3-glucan synthase | Disrupt fungal cell wall |

---

*Sources: Katzung's Basic and Clinical Pharmacology 16e; Goodman & Gilman's Pharmacological Basis of Therapeutics; Lippincott Illustrated Reviews Pharmacology; Medical Microbiology (Murray et al); IDSA/AHA/WHO Clinical Guidelines.*

ls /home/daytona/workspace/antibiotic-mcqs/

pandoc --version | head -1; which wkhtmltopdf; which weasyprint

python3 -c "import reportlab; print('reportlab ok')" 2>&1; python3 -c "from fpdf…

~/antibiotic-mcqs/generate_pdf.py

#!/usr/bin/env python3
"""
Generate a professional PDF of 150 Antibiotic MCQs for PharmD SPLE
Using ReportLab
"""

from reportlab.lib.pagesizes import A4
from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle
from reportlab.lib.units import cm
from reportlab.lib.colors import HexColor, black, white
from reportlab.platypus import (
    SimpleDocTemplate, Paragraph, Spacer, Table, TableStyle,
    PageBreak, HRFlowable, KeepTogether
)
from reportlab.lib.enums import TA_LEFT, TA_CENTER, TA_JUSTIFY
from reportlab.pdfbase import pdfmetrics
from reportlab.pdfbase.ttfonts import TTFont
import re

# ── Colour palette ─────────────────────────────────────────────────────────────
NAVY      = HexColor('#1a3a5c')
TEAL      = HexColor('#006d77')
GOLD      = HexColor('#e9c46a')
LIGHT_BG  = HexColor('#f0f4f8')
GREEN_BG  = HexColor('#d4edda')
GREEN_TXT = HexColor('#155724')
GREY      = HexColor('#6c757d')
DARK_GREY = HexColor('#343a40')
WHITE     = white

OUTPUT = '/home/daytona/workspace/antibiotic-mcqs/antibiotic_150_MCQs_PharmD_SPLE.pdf'

# ── Page template with header/footer ──────────────────────────────────────────
def make_header_footer(canvas, doc):
    canvas.saveState()
    w, h = A4

    # Header bar
    canvas.setFillColor(NAVY)
    canvas.rect(0, h - 1.4*cm, w, 1.4*cm, fill=1, stroke=0)
    canvas.setFillColor(WHITE)
    canvas.setFont('Helvetica-Bold', 10)
    canvas.drawString(1.5*cm, h - 0.9*cm,
                      '150 HIGH-YIELD ANTIBIOTIC MCQs  |  PharmD SPLE Preparation')
    canvas.setFont('Helvetica', 8)
    canvas.drawRightString(w - 1.5*cm, h - 0.9*cm,
                           f'Page {doc.page}')

    # Footer bar
    canvas.setFillColor(TEAL)
    canvas.rect(0, 0, w, 0.8*cm, fill=1, stroke=0)
    canvas.setFillColor(WHITE)
    canvas.setFont('Helvetica-Oblique', 7)
    canvas.drawString(1.5*cm, 0.25*cm,
                      'Sources: Katzung 16e  |  Goodman & Gilman  |  Lippincott Pharmacology  |  IDSA/AHA/WHO Guidelines')
    canvas.restoreState()


# ── Styles ──────────────────────────────────────────────────────────────────────
def build_styles():
    base = getSampleStyleSheet()

    cover_title = ParagraphStyle('CoverTitle',
        fontName='Helvetica-Bold', fontSize=28, textColor=NAVY,
        alignment=TA_CENTER, spaceAfter=12, leading=34)

    cover_sub = ParagraphStyle('CoverSub',
        fontName='Helvetica', fontSize=14, textColor=TEAL,
        alignment=TA_CENTER, spaceAfter=6)

    cover_note = ParagraphStyle('CoverNote',
        fontName='Helvetica-Oblique', fontSize=11, textColor=GREY,
        alignment=TA_CENTER, spaceAfter=4)

    section_hdr = ParagraphStyle('SectionHdr',
        fontName='Helvetica-Bold', fontSize=13, textColor=WHITE,
        backColor=NAVY, alignment=TA_LEFT,
        spaceBefore=14, spaceAfter=6,
        leftIndent=-0.5*cm, rightIndent=-0.5*cm,
        borderPad=6)

    q_num = ParagraphStyle('QNum',
        fontName='Helvetica-Bold', fontSize=10.5, textColor=NAVY,
        spaceBefore=10, spaceAfter=2)

    q_text = ParagraphStyle('QText',
        fontName='Helvetica', fontSize=10, textColor=DARK_GREY,
        spaceAfter=3, leading=14, alignment=TA_JUSTIFY)

    option = ParagraphStyle('Option',
        fontName='Helvetica', fontSize=9.5, textColor=DARK_GREY,
        leftIndent=0.6*cm, spaceAfter=1, leading=13)

    answer_box = ParagraphStyle('AnswerBox',
        fontName='Helvetica-Bold', fontSize=9.5, textColor=GREEN_TXT,
        backColor=GREEN_BG, leftIndent=0.4*cm, rightIndent=0.4*cm,
        spaceBefore=3, spaceAfter=2, borderPad=4)

    explain = ParagraphStyle('Explain',
        fontName='Helvetica-Oblique', fontSize=9, textColor=DARK_GREY,
        leftIndent=0.4*cm, spaceAfter=8, leading=13, alignment=TA_JUSTIFY)

    tbl_header = ParagraphStyle('TblHeader',
        fontName='Helvetica-Bold', fontSize=8.5, textColor=WHITE, alignment=TA_CENTER)

    tbl_cell = ParagraphStyle('TblCell',
        fontName='Helvetica', fontSize=8, textColor=DARK_GREY, alignment=TA_LEFT)

    return dict(
        cover_title=cover_title, cover_sub=cover_sub, cover_note=cover_note,
        section_hdr=section_hdr, q_num=q_num, q_text=q_text,
        option=option, answer_box=answer_box, explain=explain,
        tbl_header=tbl_header, tbl_cell=tbl_cell
    )


# ── Cover page ──────────────────────────────────────────────────────────────────
def build_cover(S):
    elems = []
    elems.append(Spacer(1, 3*cm))

    # Decorative top banner
    banner_data = [['150 HIGH-YIELD ANTIBIOTIC MCQs']]
    banner_tbl = Table(banner_data, colWidths=[16*cm])
    banner_tbl.setStyle(TableStyle([
        ('BACKGROUND', (0,0), (-1,-1), NAVY),
        ('TEXTCOLOR',  (0,0), (-1,-1), WHITE),
        ('FONTNAME',   (0,0), (-1,-1), 'Helvetica-Bold'),
        ('FONTSIZE',   (0,0), (-1,-1), 22),
        ('ALIGN',      (0,0), (-1,-1), 'CENTER'),
        ('TOPPADDING', (0,0), (-1,-1), 16),
        ('BOTTOMPADDING', (0,0), (-1,-1), 16),
        ('ROUNDEDCORNERS', [8, 8, 8, 8]),
    ]))
    elems.append(banner_tbl)
    elems.append(Spacer(1, 0.5*cm))

    elems.append(Paragraph('PharmD SPLE Comprehensive Preparation', S['cover_sub']))
    elems.append(Spacer(1, 0.3*cm))
    elems.append(Paragraph('All Antibiotic Classes  ·  Mechanisms  ·  Uses  ·  ADRs  ·  Contraindications  ·  Drug Interactions', S['cover_note']))
    elems.append(Spacer(1, 1.5*cm))

    # Summary box
    summary_data = [
        ['📋  150 Questions', '💊  20+ Antibiotic Classes', '🎯  SPLE-Style Format'],
        ['Detailed Explanations', 'Answer Key Included', 'Quick-Reference Tables'],
    ]
    sum_tbl = Table(summary_data, colWidths=[5.3*cm, 5.3*cm, 5.3*cm])
    sum_tbl.setStyle(TableStyle([
        ('BACKGROUND',    (0,0), (-1,0), TEAL),
        ('BACKGROUND',    (0,1), (-1,1), LIGHT_BG),
        ('TEXTCOLOR',     (0,0), (-1,0), WHITE),
        ('TEXTCOLOR',     (0,1), (-1,1), DARK_GREY),
        ('FONTNAME',      (0,0), (-1,-1), 'Helvetica-Bold'),
        ('FONTSIZE',      (0,0), (-1,-1), 10),
        ('ALIGN',         (0,0), (-1,-1), 'CENTER'),
        ('VALIGN',        (0,0), (-1,-1), 'MIDDLE'),
        ('TOPPADDING',    (0,0), (-1,-1), 10),
        ('BOTTOMPADDING', (0,0), (-1,-1), 10),
        ('GRID',          (0,0), (-1,-1), 0.5, WHITE),
        ('ROUNDEDCORNERS', [6, 6, 6, 6]),
    ]))
    elems.append(sum_tbl)
    elems.append(Spacer(1, 1.5*cm))

    topics = [
        ['SECTIONS COVERED'],
        ['Beta-Lactams (Penicillins, Cephalosporins, Carbapenems, Monobactams)'],
        ['Glycopeptides (Vancomycin)  ·  Aminoglycosides  ·  Tetracyclines/Glycylcyclines'],
        ['Macrolides  ·  Fluoroquinolones  ·  Sulfonamides/TMP  ·  Lincosamides'],
        ['Chloramphenicol  ·  Rifamycins  ·  Nitroimidazoles  ·  Linezolid  ·  Daptomycin'],
        ['Polymyxins  ·  Nitrofurantoin  ·  Fosfomycin  ·  Anti-TB Drugs (RIPE)'],
        ['Antifungals (Ampho B, Azoles, Echinocandins)  ·  Resistance Mechanisms'],
        ['PK/PD (Time- vs Concentration-dependent killing)  ·  Drug Interactions'],
        ['Special Populations  ·  Clinical Scenarios  ·  Antibiotic Stewardship'],
    ]
    topic_tbl = Table([[Paragraph(r[0], ParagraphStyle('tc',
        fontName='Helvetica-Bold' if i==0 else 'Helvetica',
        fontSize=10 if i==0 else 9,
        textColor=WHITE if i==0 else DARK_GREY,
        alignment=TA_CENTER))] for i, r in enumerate(topics)],
        colWidths=[16*cm])
    topic_tbl.setStyle(TableStyle([
        ('BACKGROUND',    (0,0), (-1,0), TEAL),
        ('BACKGROUND',    (0,1), (-1,-1), LIGHT_BG),
        ('TOPPADDING',    (0,0), (-1,-1), 6),
        ('BOTTOMPADDING', (0,0), (-1,-1), 6),
        ('GRID',          (0,0), (-1,-1), 0.3, HexColor('#c0cfe0')),
    ]))
    elems.append(topic_tbl)
    elems.append(PageBreak())
    return elems


# ── Parse the markdown file ─────────────────────────────────────────────────────
def parse_md(path):
    with open(path, 'r', encoding='utf-8') as f:
        raw = f.read()

    questions = []
    # Split into blocks by "---" separating questions
    blocks = re.split(r'\n---\n', raw)

    section = ''
    for block in blocks:
        block = block.strip()
        if not block:
            continue

        # Section header
        sec_match = re.match(r'^##\s+SECTION\s+\d+[:\s]+(.*)', block, re.MULTILINE)
        if sec_match:
            section = sec_match.group(0).strip('# ').strip()

        # Quick-reference table (keep as raw text block)
        if 'QUICK-REFERENCE' in block:
            questions.append({'type': 'ref_table', 'text': block, 'section': section})
            continue

        # Answer key summary table
        if 'ANSWER KEY SUMMARY' in block:
            questions.append({'type': 'answer_key', 'text': block, 'section': section})
            continue

        # Individual question blocks: starts with **Q\d+.**
        q_match = re.search(r'\*\*Q(\d+)\.\*\*\s*(.*?)(?=\nA\))', block, re.DOTALL)
        if not q_match:
            continue

        qnum = int(q_match.group(1))
        qtext = q_match.group(2).strip()

        # Extract options A-D
        opts = {}
        for letter in 'ABCD':
            om = re.search(rf'^{letter}\)\s*(.*?)$', block, re.MULTILINE)
            if om:
                opts[letter] = om.group(1).strip()

        # Extract answer letter
        ans_match = re.search(r'\*\*Answer:\s*([A-D])\*\*', block)
        ans_letter = ans_match.group(1) if ans_match else ''

        # Extract explanation (italicized line after answer)
        exp_match = re.search(r'\*Answer:\s*[A-D]\*\*\n\*(.*?)\*', block, re.DOTALL)
        if not exp_match:
            exp_match = re.search(r'\*\*Answer:\s*[A-D]\*\*\s*\n\*(.*?)\*', block, re.DOTALL)
        explanation = exp_match.group(1).strip() if exp_match else ''

        questions.append({
            'type': 'question',
            'num': qnum,
            'section': section,
            'qtext': qtext,
            'opts': opts,
            'ans': ans_letter,
            'explain': explanation,
        })

    return questions


# ── Build question flowables ────────────────────────────────────────────────────
def build_questions(questions, S):
    elems = []
    current_section = ''

    for q in questions:
        if q['type'] == 'answer_key':
            elems.append(PageBreak())
            elems.append(Paragraph('ANSWER KEY SUMMARY', S['section_hdr']))
            elems.append(Spacer(1, 0.3*cm))
            # Build a compact answer key table
            ans_data = [['Q', 'Ans', 'Q', 'Ans', 'Q', 'Ans', 'Q', 'Ans', 'Q', 'Ans']]
            # extract from text
            rows = re.findall(r'\|\s*(\d+)\s*\|\s*([A-D])\s*\|', q['text'])
            # group into rows of 5
            for i in range(0, len(rows), 5):
                chunk = rows[i:i+5]
                row = []
                for qn, an in chunk:
                    row += [qn, an]
                while len(row) < 10:
                    row += ['', '']
                ans_data.append(row)

            if len(ans_data) > 1:
                ak_tbl = Table(ans_data, colWidths=[1.1*cm]*10)
                ak_tbl.setStyle(TableStyle([
                    ('BACKGROUND',    (0,0), (-1,0), NAVY),
                    ('TEXTCOLOR',     (0,0), (-1,0), WHITE),
                    ('FONTNAME',      (0,0), (-1,0), 'Helvetica-Bold'),
                    ('FONTNAME',      (0,1), (-1,-1), 'Helvetica'),
                    ('FONTSIZE',      (0,0), (-1,-1), 8),
                    ('ALIGN',         (0,0), (-1,-1), 'CENTER'),
                    ('VALIGN',        (0,0), (-1,-1), 'MIDDLE'),
                    ('GRID',          (0,0), (-1,-1), 0.4, HexColor('#c0cfe0')),
                    ('ROWBACKGROUNDS', (0,1), (-1,-1), [LIGHT_BG, WHITE]),
                    ('TOPPADDING',    (0,0), (-1,-1), 4),
                    ('BOTTOMPADDING', (0,0), (-1,-1), 4),
                ]))
                elems.append(ak_tbl)
            continue

        if q['type'] == 'ref_table':
            elems.append(PageBreak())
            elems.append(Paragraph('QUICK-REFERENCE: ANTIBIOTIC MECHANISMS', S['section_hdr']))
            elems.append(Spacer(1, 0.3*cm))

            mech_data = [
                ['Class', 'Target / Site', 'Mechanism'],
                ['Beta-lactams', 'PBPs (transpeptidase)', 'Inhibit peptidoglycan cross-linking'],
                ['Vancomycin', 'D-Ala-D-Ala terminus', 'Block transglycosylation & transpeptidation'],
                ['Aminoglycosides', '30S ribosome', 'mRNA misreading; faulty protein synthesis'],
                ['Tetracyclines', '30S ribosome (A-site)', 'Block aminoacyl-tRNA binding'],
                ['Macrolides', '50S ribosome (23S rRNA)', 'Block peptidyl-tRNA translocation'],
                ['Clindamycin', '50S ribosome (23S rRNA)', 'Inhibit peptidyl transferase'],
                ['Chloramphenicol', '50S ribosome (23S rRNA)', 'Inhibit peptidyl transferase'],
                ['Linezolid', '50S ribosome (23S rRNA)', 'Block 70S initiation complex (unique)'],
                ['Fluoroquinolones', 'DNA gyrase / Topo IV', 'Inhibit DNA replication'],
                ['Rifampin', 'RNA polymerase (β subunit)', 'Inhibit transcription'],
                ['Sulfonamides', 'Dihydropteroate synthase', 'Block dihydrofolic acid synthesis'],
                ['Trimethoprim', 'DHFR', 'Block THF synthesis (sequential block with sulfa)'],
                ['Metronidazole', 'DNA', 'Free radical-induced DNA strand breaks'],
                ['Daptomycin', 'Cell membrane', 'Membrane depolarization via pore formation'],
                ['Polymyxins', 'Outer membrane (LPS)', 'Membrane disruption; ion leakage'],
                ['INH', 'InhA (enoyl-ACP reductase)', 'Block mycolic acid synthesis'],
                ['Ethambutol', 'Arabinosyltransferase', 'Block arabinoglycan synthesis'],
                ['Amphotericin B', 'Ergosterol', 'Membrane pores; electrolyte leakage'],
                ['Azoles', 'Lanosterol 14α-demethylase', 'Block ergosterol synthesis'],
                ['Echinocandins', 'β-1,3-glucan synthase', 'Disrupt fungal cell wall'],
            ]
            col_w = [4.5*cm, 5*cm, 7.5*cm]
            m_tbl = Table(mech_data, colWidths=col_w)
            m_tbl.setStyle(TableStyle([
                ('BACKGROUND',    (0,0), (-1,0), NAVY),
                ('TEXTCOLOR',     (0,0), (-1,0), WHITE),
                ('FONTNAME',      (0,0), (-1,0), 'Helvetica-Bold'),
                ('FONTSIZE',      (0,0), (-1,0), 9),
                ('FONTNAME',      (0,1), (-1,-1), 'Helvetica'),
                ('FONTSIZE',      (0,1), (-1,-1), 8.5),
                ('ROWBACKGROUNDS',(0,1), (-1,-1), [LIGHT_BG, WHITE]),
                ('GRID',          (0,0), (-1,-1), 0.4, HexColor('#c0cfe0')),
                ('ALIGN',         (0,0), (-1,-1), 'LEFT'),
                ('VALIGN',        (0,0), (-1,-1), 'MIDDLE'),
                ('TOPPADDING',    (0,0), (-1,-1), 5),
                ('BOTTOMPADDING', (0,0), (-1,-1), 5),
                ('LEFTPADDING',   (0,0), (-1,-1), 6),
            ]))
            elems.append(m_tbl)

            # ADR table
            elems.append(Spacer(1, 0.5*cm))
            elems.append(Paragraph('CRITICAL ADR PAIRS', ParagraphStyle('subhdr',
                fontName='Helvetica-Bold', fontSize=11, textColor=NAVY, spaceBefore=8, spaceAfter=4)))
            adr_data = [
                ['Antibiotic', 'Critical Adverse Effects'],
                ['Aminoglycosides', 'Nephrotoxicity + Ototoxicity (irreversible cochlear damage)'],
                ['Vancomycin', 'Red Man Syndrome (infusion) + Nephrotoxicity + Ototoxicity'],
                ['Chloramphenicol', 'Aplastic Anemia (idiosyncratic) + Gray Baby Syndrome'],
                ['Fluoroquinolones', 'Tendon Rupture (BBW) + QT Prolongation + Seizures'],
                ['Linezolid', 'Thrombocytopenia (TDM) + Serotonin Syndrome (MAOi)'],
                ['Daptomycin', 'Myopathy/Rhabdomyolysis (monitor CPK) - NOT for pneumonia'],
                ['Tetracyclines', 'Tooth discoloration (children <8) + Photosensitivity'],
                ['Metronidazole', 'Disulfiram-like reaction (alcohol) + Peripheral neuropathy'],
                ['Rifampin', 'Orange body fluids (harmless) + Potent CYP inducer'],
                ['INH', 'Peripheral neuropathy (B6 deficiency) + Hepatotoxicity'],
                ['Ethambutol', 'Optic neuritis (red-green color blindness)'],
                ['Amphotericin B', 'Nephrotoxicity (80%) + Infusion reactions (shake & bake)'],
                ['Polymyxins', 'Nephrotoxicity (30-60%) + Neurotoxicity'],
            ]
            a_tbl = Table(adr_data, colWidths=[4.5*cm, 12.5*cm])
            a_tbl.setStyle(TableStyle([
                ('BACKGROUND',    (0,0), (-1,0), TEAL),
                ('TEXTCOLOR',     (0,0), (-1,0), WHITE),
                ('FONTNAME',      (0,0), (-1,0), 'Helvetica-Bold'),
                ('FONTSIZE',      (0,0), (-1,0), 9),
                ('FONTNAME',      (0,1), (0,-1), 'Helvetica-Bold'),
                ('FONTNAME',      (1,1), (1,-1), 'Helvetica'),
                ('FONTSIZE',      (0,1), (-1,-1), 8.5),
                ('ROWBACKGROUNDS',(0,1), (-1,-1), [HexColor('#fff3cd'), WHITE]),
                ('GRID',          (0,0), (-1,-1), 0.4, HexColor('#c0cfe0')),
                ('VALIGN',        (0,0), (-1,-1), 'MIDDLE'),
                ('TOPPADDING',    (0,0), (-1,-1), 5),
                ('BOTTOMPADDING', (0,0), (-1,-1), 5),
                ('LEFTPADDING',   (0,0), (-1,-1), 6),
            ]))
            elems.append(a_tbl)
            continue

        # --- Regular question ---
        if q['section'] != current_section:
            current_section = q['section']
            elems.append(Spacer(1, 0.2*cm))
            elems.append(Paragraph(current_section, S['section_hdr']))
            elems.append(Spacer(1, 0.2*cm))

        qnum_str = f"Q{q['num']}."
        qtext_clean = re.sub(r'\*\*|__', '', q['qtext'])

        block_items = []
        block_items.append(Paragraph(f"{qnum_str}  {qtext_clean}", S['q_num']))

        for letter in 'ABCD':
            if letter in q['opts']:
                opt_text = re.sub(r'\*\*|__', '', q['opts'][letter])
                prefix = f"<b>{letter})</b>  " if letter == q['ans'] else f"{letter})  "
                color = GREEN_TXT if letter == q['ans'] else DARK_GREY
                style = ParagraphStyle(f'opt_{letter}',
                    parent=S['option'],
                    textColor=color,
                    fontName='Helvetica-Bold' if letter == q['ans'] else 'Helvetica')
                block_items.append(Paragraph(prefix + opt_text, style))

        ans_txt = f"✓  ANSWER: {q['ans']}"
        block_items.append(Paragraph(ans_txt, S['answer_box']))

        if q['explain']:
            exp_clean = re.sub(r'\*\*|__|\*', '', q['explain'])
            block_items.append(Paragraph(exp_clean, S['explain']))

        elems.append(KeepTogether(block_items))

    return elems


# ── Main ────────────────────────────────────────────────────────────────────────
def main():
    doc = SimpleDocTemplate(
        OUTPUT,
        pagesize=A4,
        leftMargin=1.8*cm, rightMargin=1.8*cm,
        topMargin=2.0*cm, bottomMargin=1.5*cm,
        title='150 High-Yield Antibiotic MCQs — PharmD SPLE',
        author='Orris Medical Education',
        subject='Antibiotic Pharmacology — Mechanisms, Uses, ADRs, Contraindications',
    )

    S = build_styles()
    story = []

    # Cover
    story += build_cover(S)

    # Parse MD
    questions = parse_md('/home/daytona/workspace/antibiotic-mcqs/antibiotic_150_MCQs_PharmD_SPLE.md')
    print(f"Parsed {len([q for q in questions if q['type']=='question'])} questions")

    # Questions
    story += build_questions(questions, S)

    doc.build(story, onFirstPage=make_header_footer, onLaterPages=make_header_footer)
    print(f"PDF saved to: {OUTPUT}")


if __name__ == '__main__':
    main()

cd /home/daytona/workspace/antibiotic-mcqs && python3 generate_pdf.py 2>&1

ls -lh /home/daytona/workspace/antibiotic-mcqs/antibiotic_150_MCQs_PharmD_SPLE.p…